4.7 Review

Targeting the heat shock response in combination with radiotherapy: Sensitizing cancer cells to irradiation-induced cell death and heating up their immunogenicity

期刊

CANCER LETTERS
卷 368, 期 2, 页码 209-229

出版社

ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2015.02.047

关键词

Radiotherapy; Immunotherapy; Hyperthermia; Heat shock response; Heat shock protein

类别

资金

  1. Deutsche Forschungsgemeinschaft [CRC914]
  2. Elite Netzwerk Bayern (iTarget Graduate Program)
  3. Heuer-Stiftung
  4. Deutsche Forschungsgemeinschaft (IRTG)

向作者/读者索取更多资源

Radiotherapy represents an essential treatment option for the majority of cancer patients in different stages of their disease. Physical achievements of the recent years led to the implementation of high precision treatment planning procedures, and image-guided dose delivery is current state of the art. Yet, radiotherapy still faces several limitations with cancer intrinsic radioresistance being a key driver of therapeutic failure. Accordingly, the mechanisms orchestrating radioresistance and their therapeutic targeting by combined modality approaches are in the center of attention of numerous radiation oncologists. In the present review, we summarize and discuss therapeutic approaches that exploit the heat shock response, either by hyperthermia or by pharmacological heat shock protein inhibition, in combination with radiotherapy. These strategies appear particularly promising, since they sensitize cancer cells to irradiation-induced cell death and at the same time have proven the potential to promote systemic anti-tumor immune mechanisms, which may target not only locally surviving tumor cells, but also distant out-of-field metastases. (C) 2015 Elsevier Ireland Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

HSP90 inhibition as a means of radiosensitizing resistant, aggressive soft tissue sarcomas

Anne Ernst, Heike Anders, Heidi Kapfhammer, Michael Orth, Roman Hennel, Karin Seidl, Nicolas Winssinger, Claus Belka, Steffen Unkel, Kirsten Lauber

CANCER LETTERS (2015)

Article Oncology

A novel HSP90 inhibitor with reduced hepatotoxicity synergizes with radiotherapy to induce apoptosis, abrogate clonogenic survival, and improve tumor control in models of colorectal cancer

Linda Kinzel, Anne Ernst, Michael Orth, Valerie Albrecht, Roman Hennel, Nikko Brix, Benjamin Frey, Udo S. Gaipl, Gabriele Zuchtriegel, Christoph A. Reichel, Andreas Blutke, Daniela Schilling, Gabriele Multhoff, Minglun Li, Maximilian Niyazi, Anna A. Friedl, Nicolas Winssinger, Claus Belka, Kirsten Lauber

ONCOTARGET (2016)

Article Immunology

Serum-Derived Plasminogen Is Activated by Apoptotic Cells and Promotes Their Phagocytic Clearance

Matthias Rosenwald, Uwe Koppe, Hildegard Keppeler, Guido Sauer, Roman Hennel, Anne Ernst, Karin Erika Blume, Christoph Peter, Martin Herrmann, Claus Belka, Klaus Schulze-Osthoff, Sebastian Wesselborg, Kirsten Lauber

JOURNAL OF IMMUNOLOGY (2012)

Review Biology

Current concepts in clinical radiation oncology

Michael Orth, Kirsten Lauber, Maximilian Niyazi, Anna A. Friedl, Minglun Li, Cornelius Maihoefer, Lars Schuettrumpf, Anne Ernst, Olivier M. Niemoeller, Claus Belka

RADIATION AND ENVIRONMENTAL BIOPHYSICS (2014)

Article Oncology

Release of monocyte migration signals by breast cancer cell lines after ablative and fractionated γ-irradiation

Roman Hennel, Nikko Brix, Karin Seidl, Anne Ernst, Heike Scheithauer, Claus Belka, Kirsten Lauber

RADIATION ONCOLOGY (2014)

Review Oncology

Dying cell clearance and its impact on the outcome of tumor radiotherapy

Kirsten Lauber, Anne Ernst, Michael Orth, Martin Herrmann, Claus Belka

FRONTIERS IN ONCOLOGY (2012)

Article Oncology

Priming anti-tumor immunity by radiotherapy: Dying tumor cell-derived DAMPs trigger endothelial cell activation and recruitment of myeloid cells

Julia Krombach, Roman Hennel, Nikko Brix, Michael Orth, Ulrike Schoetz, Anne Ernst, Jessica Schuster, Gabriele Zuchtriegel, Christoph A. Reichel, Susanne Bierschenk, Markus Sperandio, Thomas Vogl, Steffen Unkel, Claus Belka, Kirsten Lauber

ONCOIMMUNOLOGY (2019)

Article Oncology

S100A10 Is a Critical Mediator of GAS6/AXL-Induced Angiogenesis in Renal Cell Carcinoma

Yiren Xiao, Hongjuan Zhao, Lei Tian, Rosalie Nolley, Anh N. Diep, Anne Ernst, Katherine C. Fuh, Yu Rebecca Miao, Rie von Eyben, John T. Leppert, James D. Brooks, Donna M. Peehl, Amato J. Giaccia, Erinn B. Rankin

CANCER RESEARCH (2019)

Article Oncology

Priming of Anti-tumor Immune Mechanisms by Radiotherapy Is Augmented by Inhibition of Heat Shock Protein 90

Anne Ernst, Roman Hennel, Julia Krombach, Heidi Kapfhammer, Nikko Brix, Gabriele Zuchtriegel, Bernd Uhl, Christoph A. Reichel, Benjamin Frey, Udo S. Gaipl, Nicolas Winssinger, Senji Shirasawa, Takehiko Sasazuki, Markus Sperandio, Claus Belka, Kirsten Lauber

FRONTIERS IN ONCOLOGY (2020)

Review Oncology

Small extracellular vesicles: Non-negligible vesicles in tumor progression, diagnosis, and therapy

Xinru Zhou, Yin Jia, Chuanbin Mao, Shanrong Liu

Summary: Small extracellular vesicles (sEVs), such as exosomes, have emerged as crucial targets for liquid biopsy and promising drug delivery vehicles in tumor progression. They can serve as biomarkers for tumor diagnosis and as drug carriers for cancer treatment.

CANCER LETTERS (2024)

Article Oncology

HMGB1 in the interplay between autophagy and apoptosis in cancer

Ruochan Chen, Ju Zhu, Xiao Zhong, Jie Li, Rui Kang, Daolin Tang

Summary: The interplay between autophagy and apoptosis plays a crucial role in tumorigenesis and cancer therapy, with HMGB1 serving as a key regulator in these processes.

CANCER LETTERS (2024)

Article Oncology

Epigenetic inhibition of CTCF by HN1 promotes dedifferentiation and stemness of anaplastic thyroid cancer

Zongfu Pan, Xixuan Lu, Tong Xu, Jinming Chen, Lisha Bao, Ying Li, Yingying Gong, Yulu Che, Xiaozhou Zou, Zhuo Tan, Ping Huang, Minghua Ge

Summary: This study uncovered the emerging role of HN1 in promoting dedifferentiation of anaplastic thyroid cancer (ATC) cells. HN1 negatively regulated the thyroid differentiation markers and had an inhibitory effect on the transcriptional activation of CTCF, thereby influencing the chromatin accessibility of thyroid differentiation genes.

CANCER LETTERS (2024)

Article Oncology

Autophagy machinery in glioblastoma: The prospect of cell death crosstalk and drug resistance with bioinformatics analysis

Yi Qin, Shengjun Xiong, Jun Ren, Gautam Sethi

Summary: Autophagy plays an important regulatory role in glioblastoma, and its dysregulation can lead to drug resistance and radioresistance. It also affects stem cell characteristics, overall growth, and metastasis. Therefore, autophagy is a promising target for glioblastoma therapy.

CANCER LETTERS (2024)

Article Oncology

Elevated 2-oxoglutarate antagonizes DNA damage responses in cholangiocarcinoma chemotherapy through regulating aspartate beta-hydroxylase

Katsuya Nagaoka, Xuewei Bai, Dan Liu, Kevin Cao, Joud Mulla, Chengcheng Ji, Hongze Chen, Muhammad Azhar Nisar, Amalia Bay, William Mueller, Grace Hildebrand, Jin-Song Gao, Shaolei Lu, Hiroko Setoyama, Yasuhito Tanaka, Jack R. Wands, Chiung-Kuei Huang

Summary: This study found that serum 2-OG levels in cholangiocarcinoma patients are associated with the effectiveness of chemotherapy. Patients with progressive disease showed significantly higher levels of serum 2-OG compared to stable disease and partial response patients. The study also revealed that overexpression of ASPH mimics the effects of 2-OG, and knockdown of ASPH improves chemotherapy. Targeting ASPH enhances the effects of chemotherapy by modulating ATM and ATR, two key regulators of DDRs.

CANCER LETTERS (2024)